2024 Q1 Form 10-Q Financial Statement

#000167479624000015 Filed on June 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $32.69K $35.47K $38.08K
YoY Change -14.15% 2.54% 2.01%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $32.69K $35.47K $38.08K
YoY Change -14.15% 2.54% 1.99%
Operating Profit -$32.69K -$38.08K
YoY Change -14.15% 1.99%
Interest Expense $1.489K -$1.430K $1.211K
YoY Change 22.96% 27.68% 37.46%
% of Operating Profit
Other Income/Expense, Net -$1.489K -$1.211K
YoY Change 22.96% 37.46%
Pretax Income -$34.18K -$36.90K -$39.29K
YoY Change -13.0% 3.33% 2.81%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$34.18K -$36.90K -$39.29K
YoY Change -13.0% 3.33% 2.81%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01 -$0.01
COMMON SHARES
Basic Shares Outstanding 5.249M shares 5.249M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $840.00 $1.530K $120.00
YoY Change 600.0% 705.26% -7.69%
Cash & Equivalents $838.00 $1.530K $115.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $838.00 $1.530K $115.00
YoY Change 628.7% 705.26% -9.45%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $838.00 $1.530K $115.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $838.00 $1.530K $115.00
YoY Change 628.7% 705.26% -9.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $512.3K $2.280K $392.3K
YoY Change 30.59% -99.37% 43.95%
Accrued Expenses $14.49K $493.0K $8.910K
YoY Change 62.63% 6302.6% 96.26%
Deferred Revenue
YoY Change
Short-Term Debt $100.3K $98.32K $84.08K
YoY Change 19.31% 29.23% 35.44%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $627.1K $593.6K $485.3K
YoY Change 29.23% 33.08% 43.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $627.1K $593.6K $485.3K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $627.1K $593.6K $485.3K
YoY Change 29.23% 33.08% 43.09%
SHAREHOLDERS EQUITY
Retained Earnings -$6.049M -$6.015M -$5.908M
YoY Change 2.39% 2.49% 2.54%
Common Stock $5.248K $5.248K $5.248K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$626.2K -$592.1K -$485.1K
YoY Change
Total Liabilities & Shareholders Equity $838.00 $1.530K $115.00
YoY Change 628.7% 705.26% -9.45%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q1
OPERATING ACTIVITIES
Net Income -$34.18K -$36.90K -$39.29K
YoY Change -13.0% 3.33% 2.81%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$32.69K -$5.480K -$8.075K
YoY Change 304.8% 19.39% 13.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $32.00K 5.000K $8.000K
YoY Change 300.0% 11.11% 14.29%
NET CHANGE
Cash From Operating Activities -$32.69K -5.480K -$8.075K
Cash From Investing Activities $0.00 0.000 $0.00
Cash From Financing Activities $32.00K 5.000K $8.000K
Net Change In Cash -$688.00 -480.0 -$75.00
YoY Change 817.33% 433.33% -23.47%
FREE CASH FLOW
Cash From Operating Activities -$32.69K -$5.480K -$8.075K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Entity File Number
EntityFileNumber
000-15303
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
HST Global, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
73-1215433
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
509 Old Great Neck Road
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Virginia Beach
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23454
CY2024Q1 dei City Area Code
CityAreaCode
800
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
961-4750
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5248582 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
838 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1526 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
838 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1526 usd
CY2024Q1 us-gaap Assets
Assets
838 usd
CY2023Q4 us-gaap Assets
Assets
1526 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2275 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2275 usd
CY2024Q1 fil Accounts Payable And Accrued Expenses Related Parties
AccountsPayableAndAccruedExpensesRelatedParties
510000 usd
CY2023Q4 fil Accounts Payable And Accrued Expenses Related Parties
AccountsPayableAndAccruedExpensesRelatedParties
480000 usd
CY2024Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
100319 usd
CY2023Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
98319 usd
CY2024Q1 fil Accrued Related Party Interest
AccruedRelatedPartyInterest
14488 usd
CY2023Q4 fil Accrued Related Party Interest
AccruedRelatedPartyInterest
12999 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
627082 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
593593 usd
CY2024Q1 us-gaap Liabilities
Liabilities
627082 usd
CY2023Q4 us-gaap Liabilities
Liabilities
593593 usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
5248 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5248 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5417236 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5417236 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6048728 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6014551 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-626244 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-592067 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
838 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1526 usd
CY2024Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
CY2024Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
30000 usd
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
30000 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2688 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8075 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
32688 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
38075 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32688 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-38075 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
1489 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
1211 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1489 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1211 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34177 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39286 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-34177 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-39286 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5248582 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5248582 shares
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-34177 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-39286 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
0 usd
CY2024Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1489 usd
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1212 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32688 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38075 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2000 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
8000 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
30000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
30000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-688 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-75 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1526 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
838 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115 usd
CY2024Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><b>NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES </b></p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">HST Global, Inc. (the "Company") was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition was accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc. At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations.  Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company was headquartered in Hampton, VA on March 31, 2024 and is currently headquartered in Virginia Beach, Virginia.</p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">The Company was founded as an Integrated Health and Wellness Biotechnology company with a plan to develop and /or acquire a network of Wellness Centers worldwide that would be primarily focused on the homeopathic and alternative treatment of late stage cancer. </p> <p style="font:11pt Times New Roman;margin:0">The Company is a dynamic public holding company, strategically focused on the intersection of the Healthcare, Software, and Transportation industries. With a commitment to innovation and excellence, HST Global specializes in identifying potential investment opportunities and spearheading ventures within these critical sectors.</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><b><i>Core Industries</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><kbd style="position:absolute;font:11pt Times New Roman;margin-left:0pt">•</kbd><kbd style="margin-left:36pt"></kbd><i>Healthcare</i>: HST Global seeks to invest in companies that are at the forefront of medical technology, healthcare services, and solutions that enhance patient care and improve clinical outcomes. </p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><kbd style="position:absolute;font:11pt Times New Roman;margin-left:0pt">•</kbd><kbd style="margin-left:36pt"></kbd><i>Software</i>: Recognizing the transformative power of technology, the Company seeks to fund and develop cutting-edge software solutions that drive efficiency, productivity, and growth across various industries. </p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><kbd style="position:absolute;font:11pt Times New Roman;margin-left:0pt">•</kbd><kbd style="margin-left:36pt"></kbd><i>Transportation</i>: With an eye on the future, the Company is involved in ventures that revolutionize how goods and people move, focusing on sustainable and intelligent transportation systems. </p> <p style="font:11pt Times New Roman;margin:0">Investment Philosophy</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><kbd style="margin-left:36pt"></kbd>The Company's investment philosophy centers on creating value through strategic acquisitions and the nurturing of innovative ideas into successful business ventures. By leveraging its industry insight and operational expertise, the Company aims to generate sustainable earnings growth and long-term value for its shareholders. </p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><b><i>Vision and Mission</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><i>Vision</i>: To be a leading holding company known for transforming high-potential ideas into leading enterprises in Healthcare, Software, and Transportation.</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><i>Mission</i>: To invest in and develop businesses that lead their respective industries while delivering consistent returns and growth to our stakeholders.</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying interim condensed financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnotes necessary for a complete presentation of the Company’s financial </p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">position, results of operations, cash flows, and stockholders’ equity in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of the Company as of and for the fiscal year ended December 31, 2023. The results of operations for the period ended March 31, 2024, are not necessarily indicative of the results for a full-year period.</p>
CY2024Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><span style="border-bottom:1px solid #000000">Basis of Presentation</span></p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying condensed financial statements and related notes include the activity of the Company and have been prepared in accordance with U.S. GAAP and with the rules and regulations of the SEC to Form 10-K and 10-Q.  </p>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><span style="border-bottom:1px solid #000000">Use of Estimates</span></p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>

Files In Submission

Name View Source Status
0001674796-24-000015-index-headers.html Edgar Link pending
0001674796-24-000015-index.html Edgar Link pending
0001674796-24-000015.txt Edgar Link pending
0001674796-24-000015-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hstc-20240331.htm Edgar Link pending
hstc-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hstc-20240331_cal.xml Edgar Link unprocessable
hstc-20240331_def.xml Edgar Link unprocessable
hstc-20240331_lab.xml Edgar Link unprocessable
hstc-20240331_pre.xml Edgar Link unprocessable
hstc-20240331_htm.xml Edgar Link completed